Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATED-4-PC
CTR20254935Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selumetinib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events, adverse events of special interest, and serious adverse events, Incidence of AZD6621 treatment discontinuation due to toxicity and 3 more. Started Dec 2025; status: active.
02
Drugs
selumetinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20254935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254935.